Winning Stock Forecast: Celsion Corp. (NASDAQ: CLSN) Gained Nearly 30% Up Move For Promising Research Pipeline

Winning Stock Forecast

“Celsion continues to make significant progress with our two ongoing clinical development programs for ThermoDox® and GEN-1.  With sound fundamentals and a strong balance sheet, we are well positioned to complete enrollment in our ongoing 550 patient global, pivotal Phase III OPTIMA Study in primary liver cancer and to initiate our 130 patient Phase I/II randomized OVATION II Study in newly diagnosed patients with ovarian cancer in June 2018 and reporting clinical findings from the Phase I cohort of 12 patients of the OVATION II by the end of 2018.” -Michael H. Tardugno, chairman

Read More